A Phase I1 clinical trial of the combination of 5-fluorouracil (5-FU) and recombinant alpha-2a-interferon (a-2a-IFN) was conducted in 44 patients. Patients had not received chemotherapy previously and had measurable metastatic gastric carcinoma. 5-FU was administered as a continuous infusion at a do
โฆ LIBER โฆ
A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma
โ Scribed by The Gastrointestinal Tumor Study Group
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 476 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
A Phase II trial of 5-fluorouracil and r
โ
Richard Pazdur; Jaffer A. Ajani; Rodger Winn; James Bearden; Robert J. Belt; Sus
๐
Article
๐
1992
๐
John Wiley and Sons
๐
English
โ 468 KB
๐ 2 views
Phase II evaluation of fluorouracil and
โ
Richard Pazdur; Jaffer J. Ajani; James L. Abbruzzese; Robert J. Belt; Shaker R.
๐
Article
๐
1992
๐
John Wiley and Sons
๐
English
โ 421 KB
๐ 1 views
A phase I-II trial of the combination of
โ
Edward T. Creagan; Charles L. Loprinzi; David L. Ahmann; Daniel J. Schaid
๐
Article
๐
1988
๐
John Wiley and Sons
๐
English
โ 325 KB
๐ 1 views
A phase I trial of 5-fluorouracil, folin
โ
Ronald M. Bukowski; Go Inoshita; Prasad Yalavarthi; Siva Murthy; Vicki Gibson; G
๐
Article
๐
1992
๐
John Wiley and Sons
๐
English
โ 427 KB
๐ 2 views
A north central cancer treatment group P
โ
Henry C. Pitot; James A. Knost; Michelle R. Mahoney; John Kugler; James E. Krook
๐
Article
๐
2000
๐
John Wiley and Sons
๐
English
โ 94 KB
๐ 2 views
Recombinant alpha-2b-interferon enhances
โ
Giovanni Scambia; Pierluigi Benedetti Panici; Stefano Iacobelli; Gabriela Baiocc
๐
Article
๐
1990
๐
John Wiley and Sons
๐
English
โ 372 KB
๐ 1 views
The circulating levels of a 90-kilodalton (K) tumor-associated antigen were measured in the blood of 43 patients with gynecologic and breast malignancies who underwent a short course of recombinant alpha-2b-interferon (rIFN a-zb) (3 million U/m2/d intramuscularly [IM] for 3 days). Of the 43 patients